Media

As part of the 25th anniversary celebrations of >>venture>>, Daniela contributed an opinion piece on how we can better nurture startups in Switzerland. Newsroom article le matin dimanche (French)

The Swiss daily business newspaper Agefi published an interview with our CEO Daniela Marino following the announcement that CUTISS started onsite denovoSkin production, at its very own GMP facility. This is an exciting milestone for the company, resulting in greater production flexibility and scale-up opportunities. Newsroom Link to Interview

The popular French science magazine Sciences et Avenir has published an article explaining the science behind our denovoSkin and denovoCast innovations, and the promise that this brings to patients suffering from severe skin burns and injuries. The journalist had visited CUTISS to see this for herself and to speak with our CEO Daniela and CIO Vincent. “Swiss researchers have succeeded in automating the manufacture of autologous skin, produced from the patient’s own cells. An innovation that will benefit burn victims in the future. Reportage from the laboratory of this promising start-up near Zurich, Switzerland.” The article was also published in the monthly edition of the magazine, February 2022. Newsroom Link to article

Swiss national television RTS came to CUTISS recently to find out about the denovoSkin, and to hear from our CIO Vincent about the promising potential of automation to scale up skin tissue bioengineering. The CUTISS segment was broadcast as part of RTS’s business program T.T.C. (Toutes taxes comprises) and is available on playback (in French) using the link below. https://www.youtube.com/watch?v=fK0Nmza1ECs Newsroom LInk to program

The Swiss national television channel RSI La 1 recently came to our offices to take a closer look at our work to develop denovoSkin, the personalized, bioengineered skin graft for children and adults suffering from large skin defects, such as severe burns. The interview with Daniela Marino was part of their monthly program Come va?, the popular science show exploring current health and medical topics, and this month’s episode focused on our body’s largest organ: skin. The episode is available on playback (in Italian) with the link below. Newsroom LInk to episode

As part of the journal’s “Innovations in wound care” section, the latest edition features a guest editorial by our CEO Daniela Marino and CIO Vincent Ronfard. When patients suffer from large and severe skin injuries affecting more than 50% of the body, such as burns, then the current standard of care – autografting – presents real challenges. New approaches to bioengineering skin could change the paradigm for large burn treatment. But even so, other challenges remain, such as mainly manual, time-consuming and costly production. Our authors put forward that automation is the answer, meeting three key objectives: reduction in manufacturing time, improved skin graft quality and safety, and decreased costs. CUTISS has developed the denovoSkin, an autologous bioengineered dermo-epidermal skin graft, intended to provide permanent skin coverage with minimal scarring. It is currently in phase II clinical trials, and is manufactured manually in a fully equipped cleanroom by highly skilled personnel. The future of denovoSkin is the automation of its manufacturing process, and CUTISS has already produced groundbreaking research and development grade prototypes for the automated production of denovoSkin. At this moment, CUTISS remains the industry pioneer in the automation of bioengineered skin manufacturing. Read the ARTICLE for further insights on the challenges and opportunities in regenerative medicine. Newsroom LInk to FULL Article

Article published by Isabelle Mitchell, Top 100 Swiss Startup Magazine 2021 on 08.09.2021 20:32 Last year’s winner is this year’s runner-up: The CUTISS team wins silver at the TOP 100 Swiss Startup Award 2021 for developing unique personalized skin technology to treat skin defects. CUTISS’s denovoSkin™ is a safe, effective, and accessible therapy for children and adults who suffer large-scale burns or scalds. The human skin grafts of the Zurich-based biotech startups are expected to result in a minimally scarring outcome after transplantation. Daniela Marino (CEO) and Fabienne Hartmann-Fritsch (CCO) founded the CUTISS in 2016. Read the full article here

swissinfo.ch  “A Swiss company is offering hope to the more than 11 million people worldwide who suffer serious burns every year. The company is launching a revolutionary machine capable of generating skin that can be grafted in large quantities using a sample provided by the patient.” read more Photo: Copyright CSEM Newsroom LInk to article on swissinfo.ch

LE TEMPS, Wednesday, 25 June 2021 INNOVATION The Start-up Cutiss has taken an important step forward. With the CSEM, it has developed a machine allowingto automate the production of personalized skin grafts. Read the full article in French only. Photo: Copyright CSEM Newsroom LInk to Article

TeleTicino, Ticinonews 2e edizione 24.6.2021 Interview with Dr. Daniela Marino and reportage on CUTISS’s unveiling of the denovoCast, the world’s first automated machine to produce customized skin tissue grafts for adults and children with severe skin injuries, such as deep burns.  Watch the interview and reportage starting at minute 12:43.  Newsroom LInk to video